Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

BioXcel drug to treat Mass General COVID-19 patients

Massachusetts General Hospital will use a New Haven biotechnology company’s experimental agitation drug to treat symptoms of “ICU delirium” in critically ill patients hospitalized with...

| By Kelley Gipson

Drug giants create fund for antibiotic startups

Twenty of the world’s largest pharmaceutical companies on Thursday announced the creation of a $1 billion fund to buoy financially strapped biotech start-ups that are...

| By Kelley Gipson

Pfizer & BioNTech gain Fast Track re SARS vaccine

Pfizer and BioNTech report that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to...

| By Kelley Gipson

Kleo COVID-19 drug gets $5M from Gates Foundation

Kleo Pharmaceuticals, the five-year-old New Haven biotech based in Science Park, has secured a $5 million grant from the Bill & Melinda Gates Foundation for its...

| By Kelley Gipson

CT welcoming NY companies tired of virus commute

As the coronavirus pandemic has reshuffled the economic landscape across the country, Connecticut is targeting small companies with top executives who may have grown tired...

| By Kelley Gipson

Cybrexa advances re solid tumor treatment

Cybrexa Therapeutics has successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its proposed IND and Phase I/II...